The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $59.21, reflecting a +0.03% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol Myers Squibb has been a strong performer in the six months, rising over 23% in that time. Investors desiring to ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

The quarter's results, reaffirmed Bristol Myers Squibb's financial health and strategic focus despite ongoing competition from generics manufacturers impacting its legacy portfolio of drugs.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s worst performing stocks. Wall Street’s main indices bounced back on ...

The FDA accepted Bristol Myers' sBLA for Opdivo plus Yervoy as a first-line treatment for MSI-H/dMMR metastatic colorectal cancer. The submission, backed by Phase 3 CheckMate -8HW data ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...